Reviewing MeiraGTx (NASDAQ:MGTX) and aTyr Pharma (NASDAQ:ATYR)

MeiraGTx (NASDAQ:MGTX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

MeiraGTx has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares MeiraGTx and aTyr Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
aTyr Pharma	N/A	-95.89%	-69.67%

Valuation and Earnings

This table compares MeiraGTx and aTyr Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$397.50 million	2.64	-$114.20 million	$0.71	15.37
aTyr Pharma	$190,000.00	157.46	-$74.12 million	($0.62)	-0.49

aTyr Pharma has lower revenue, but higher earnings than MeiraGTx. aTyr Pharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for MeiraGTx and aTyr Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	3	5	1	2.78
aTyr Pharma	1	0	1	1	2.67

MeiraGTx currently has a consensus target price of $24.71, suggesting a potential upside of 126.53%. Given MeiraGTx’s stronger consensus rating and higher possible upside, equities research analysts plainly believe MeiraGTx is more favorable than aTyr Pharma.

Summary

MeiraGTx beats aTyr Pharma on 12 of the 14 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.